Warning Letter Close-Outs – September 2015
This article was originally published in The Gray Sheet
Executive Summary
Twelve FDA close-out letters were released in September.
You may also be interested in...
Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.
Operation Warp Speed For Rare Diseases? US FDA Is Considering Pilot Programs
CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.